Subscription Required

Only paid subscribers* to Drug Benefit News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Drug Benefit News receive

  • 24 biweekly issues (8 pages) of timely news and insightful strategies for reducing costs and improving outcomes, delivered First Class by U.S. Mail and electronically
  • Special E-Alerts when timely news breaks
  • Access to your subscriber-only web page with:
    • A posting of the latest issue
    • Searchable archives of all articles for the past three years
    • A chronological posting of back issues for three years
  • Recent stories of interest and hot topic articles grouped for convenient reading and regular postings from your editor
View a sample and get more information
October 24, 2014

Recent Stories of Interest

From Drug Benefit News - Less than a year after its oral hepatitis C treatment Sovaldi (sofosbuvir) hit the market, Gilead Sciences, Inc. on Oct. 10 received FDA approval to market its much anticipated combination pill Harvoni (ledipasvir and sofosbuvir). As the first single tablet not requiring the use of interferon or ribavirin and offering cure rates of 94% to 99%, Harvoni is considered a breakthrough treatment for hepatitis C. Read more

While Medicare Advantage prescription drug (MA-PD) plans continue to earn strong star… Read more

Several PBMs this year launched programs to control a sudden and alarming… Read more

A new limited pharmacy network that was launched by two major Las… Read more

From the Editor

Welcome to your Drug Benefit News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with comments on the last issue of Drug Benefit News, story ideas for future issues or any other suggestions you have that can make the newsletter more useful for you.

October 29, 2014
Express Scripts Reports Third-Quarter Earnings

Express Scripts reports third-quarter 2014 net income of $582.3 million, or 78 cents per share, up from $426.million, or 54 cents per share, for the year-ago period.

October 21, 2014
Senator May Hold Hearing on Hep C Drug Prices, Effect on VA

Sen. Bernard Sanders (I-Vt.) may hold hearing on how costs for new hep C drugs are impacting the VA; department spokesperson says more than 5,300 veterans have been treated with Sovaldi.

October 20, 2014
CVS/caremark May Charge Extra for Using Tobacco-Selling Pharmacies

CVS/caremark may soon be charging consumers extra for using tobacco-selling pharmacies, says Pharmalot.

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to!

Why do I need to register?